Project Red: Risk Scenarios (Revised 2nd April 2002)					
Scenarios		**Units**	**Base Case Assumption**	**Possible Alternative Outcomes**	
				Low	High
Plasma testable for vCJD	UK authority approved vCJD in plasma test available and in widespread use	Years	5	2	>12
	Impact on UK donor response	% reduction	0	0	-100
	Impact on USA donor response	% reduction	0	0	-100
	FDA approve mixing of UK and USA plasma	Years	>12	5	>12
	FDA approve mixing of Continental European and USA plasma	Years	>12	5	>12
	Impact on the number of potentially approved donors in the USA	% increase	0	0	10
Prevention of use of paid plasma donors	Pan European policy approved and enforced by UK government	Years	>12	5	>12
Use of Continental European sourced plasma	Required by EU	Years	>12	5	>12
	Restricted owing to vCJD or other concerns, resulting in switch to USA sourced plasma	% switch of demand to USA	0	0	100
NHS product sourcing directed	To BPL, timing	Years	>12	3	>12
	To BPL, proportion	%	0	0	100
	To most commercial source, timing	Years	>12	3	>12
	To most commercial source, proportion	%	0	0	100
Access to US plasma	Restricted by US domestic considerations	% reduction	0	0	100
	Restricted by donor shortage	% reduction	0	0	100
	Restricted by demand exceeding supply	% reduction	0	0	100
	Curtailed by quality problems	% reduction	0	0	100

Project Red: Risk Scenarios (Revised 2nd April 2002)					
Scenarios		**Units**	**Base Case Assumption**	**Possible Alternative Outcomes**	
				Low	High
Use of recombinants	Factor 8 and 9 switch to 100% recombinants	Years	4	3	10
Gene therapy development	Impact on demand for plasma sourced IVIG by when	Years	>12	>12	5
	Impact on volume growth of IVIG	% impact	0	0	-20
Increase demand for IVIG	New indications identified that are treatable with IVIG resulting in increased demand for plasma	% growth in IVIG demand p.a.	10	5	20
vCJD in USA	Significant appearance of vCJD in US population not attributable to visits to Europe before vCJD test available	Change in availability of US plasma, %	0	0	-100
BSE in USA	Significant appearance of BSE in US cattle before vCJD test available	Change in availability of US plasma, %	0	0	-100
Force Majeure	Elimination of output from BPL plant	% change in output prices	0	0	Double
	Contamination of output from BPL plant	% change in output prices	0	0	Double
	Elimination of output from other significant fractionating plant	% change in output prices	0	0	Double